Why Myriad Genetics, Inc.’s (MYGN) Stock Is Down 5.46%
As of Tuesday, October 06, Myriad Genetics, Inc.’s MYGN share price has dipped by 5.46%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Commentary & Analysis
Why Myriad Genetics, Inc.’s (MYGN) Stock Is Up 6.40%
As of Friday, October 02, Myriad Genetics, Inc.’s MYGN share price has surged by 6.40%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Myriad Genetics, Inc.’s (MYGN) Stock Is Down 5.86%
As of Tuesday, September 22, Myriad Genetics, Inc.’s MYGN share price has dipped by 5.86%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Is Myriad Genetics, Inc. (MYGN) Overvalued?
We dive into why Myriad Genetics, Inc. (MYGN) could be considered overvalued on 2026-09-17, based on AAII’s Value Score and Grade.Jenna Brashear
Why Myriad Genetics, Inc.’s (MYGN) Stock Is Down 5.80%
As of Friday, September 18, Myriad Genetics, Inc.’s MYGN share price has dipped by 5.80%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $438.1 | $249.2 | 36% |
|
| Shares Out (Mil) | 94.8 | 53.9 | 61% |
|
| Institutional Ownership | 95.2% | 93.0% | 66% |
|
| Float (Mil) | 79.3 | 41.4 | 56% |
|
| Beta | 1.67 | 0.95 | 86% |
|
| Avg Daily Volume (000s) | 1,829 | 631 | 79% |
|
| Price Change (52-week) |
(39.4%) | 49.2% | 23% |
|
| Growth | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 8.2% | 12.5% | 51% |
|
| Net Income (5yr) | (47.1%) | (10.1%) | 8% |
|
| EPS (5yr) | (41.0%) | 15.8% | 5 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (1.3%) | (15.7%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 9 | 9 | |
| Current EPS | ($0.198) | ($0.739) | ($0.582) | |
| Month Ago EPS | ($0.213) | ($0.762) | ($0.584) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $0.071 | $0.048 | $0.151 | |
| Year/Year Chg | (57.0%) | (81.3%) | (88.2%) | |
| Financials | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $807 | $37 | 47% |
|
| Net Income (TTM) (Mil) | ($113) | ($44) | 10% |
|
| EPS (TTM) | ($1.202) | ($1.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | $8 | ($33) | 37% |
|
| Net Cash Flow (TTM) (Mil) | $33 | $2 | 66% |
|
| Long-Term Debt (Q1) (Mil) | $203 | $4 | 50% |
|
| Enterprise Value (Q1) (Mil) | $397 | $175 | 32% |
|
| Valuation | MYGN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.44 | 2.42 | 39% |
|
| P/E | na | 19.2 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | MYGN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 68.8% | 67.3% | 80% |
|
| Net Margin | (14.0%) | (74.8%) | 19% |
|
| ROA | (17.1%) | (47.7%) | 21% |
|
| ROE | (32.5%) | (54.6%) | 19% |
|
| Liabilities to Assets | 52.4% | 29.3% | 45% |
|
| F-Score | 5 | 3 | 50% |
|
Myriad Genetics, Inc. did not pass any screens on 10/5/2026.
